Updates on COVID-19 (including visitor restrictions and mask requirements), monkeypox and flu. See Communicable Disease Updates

Your browser is out-of-date!

Internet Explorer 11 has been retired by Microsoft as of June 15, 2022. To get the best experience on this website, we recommend using a modern browser, such as Safari, Chrome or Edge.

×

Hyperfractioned Regional Nodal Irradiation for women with invasive breast cancer

Trial ID:
IRB-22-7881
Ray Lin, M.D.
This study will test the safety and effectiveness of regional-nodal irradiation given over 3 weeks compared to the standard of 5 weeks.

Inclusion Criteria

Patients must:
  • Be 18 years or older
  • Have pathologically confirmed invasive breast cancer
  • Prior mastectomy or lumpectomy with axillary evaluation

Exclusion Criteria

Patients must not:
  • Have clinical or pathological evidence of metastases
  • Have cancer diagnosed in both breasts
  • Have had previous irradiation to breast, neck, or chest

Additional Info

  • Radiation treatments will be performed at Prebys Cancer Center in Hillcrest and Scripps MD Anderson Cancer Center in La Jolla.
  • Each participant will be followed for 10 years and will be expected to complete a series of questionnaires at certain time points.
  • For more information, search for NCT02912312 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org